TOP2A and neoplasm: Preclinical models and early clinical trials have demonstrated the efficacy of TOP2A inhibitors, either as monotherapy or in combination with other chemotherapeutic agents, in reducing tumor burden and improving patient outcomes, especially in platinum-sensitive recurrent disease.